RFA-IP-22-001: Research on the Epidemiology, Prevention and Control of Influenza and Other Respiratory Viruses in India
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2022.
Centers for Disease Control and Prevention - ERA offered grants of up to $2.0 million (at least $1.5 million) to the applicants described in the notice. It expected to make one award worth $10.0 million in total. Applications closed on May 9, 2022.
From the official notice on Grants.gov, last changed May 4, 2022. Checked November 7, 2026.
- Award ceiling$2.0 million
- Award floor$1.5 million
- Total funding$10.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 8, 2022 |
|---|---|
| Deadline | May 9, 2022 |
| Archived by Grants.gov | May 29, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
All-India Institute for Medical Sciences (AIIMS, New Delhi)
Is this a realistic fit?
- Past Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases awards averaged $1.9 million; this notice allows up to $2.0 million per award.
- Most of the program's money (84% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to support research to estimate the incidence of influenza and other respiratory viruses (such as SARS-CoV-2) among working-age adults and other priority populations in India to strengthen the evidence base and to help inform influenza vaccine policy in India. An additional goal is to identify risk factors that contribute to the influenza and/or SARS-CoV-2 burden in India to identify effective strategies to reduce disease burden. The overarching goal is to identify potential barriers to influenza and/or SARS-CoV-2 vaccination in the priority populations.
Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases (93.083) awarded $58.2 million across 30 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Council of Medical Specia | Illinois | 1 | $40.4 million |
| Post-Acute and Long-Term Care Medical Association, Inc. | Maryland | 1 | $7.1 million |
| National Health Laboratory Service | 1 | $3.1 million | |
| All India Institute of Medical Sciences | 1 | $1.0 million | |
| American Cancer Society, Inc | Georgia | 2 | $900,000 |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-IP-22-001 still open?
No. It closed on May 9, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Research on the Epidemiology, Prevention and Control of Influenza and Other Respiratory Viruses in India?
Centers for Disease Control and Prevention - ERA accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Research on the Epidemiology, Prevention and Control of Influenza and Other Respiratory Viruses in India?
Closed May 9, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.0 million each. About $10.0 million in total for one award.
Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before?
The largest recipients over five fiscal years were Council of Medical Specia, Post-Acute and Long-Term Care Medical Association, Inc., National Health Laboratory Service. The program made 30 awards worth $58.2 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)